Start Date
Not specified
APT-1011 3 mg HS
APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
University of Pennsylvania, Philadelphia
Regional Gastroenterology Associates of Lancaster, Ltd., Wyomissing
MGG Group Co., Inc., Chevy Chase
Gastro Center of Maryland, Columbia
Clinical and Translational Research Center (CTRC), Chapel Hill
Carolina Research, Greenville
Summit Clinical Research, Athens
Endoscopic Research, Inc., Orlando
Nature Coast Clinical Research, Inverness
Great Lakes Gastroenterology, Mentor
Northshore Gastroenterology Research LLC, Westlake
Gastro Health Research, Cincinnati
Bernstein Clinical Research Center, LLC, Cincinnati
Clinical Research Institute of Michigan LLC, Chesterfield
Henry Ford Health System, Novi
West Michigan Clinical Research Center, Wyoming
University of Iowa Hospitals and Clinics, Iowa City
MNGI Digestive Health, P.A., Minneapolis
Minnesota Gastroenterology PA Plymouth Endoscopy Center Clinic, Plymouth
Rapid City Medical Center LLP, Rapid City
Bozeman Health Clinical Research, Bozeman
Clinical Research Professionals, Chesterfield
Arkansas Gastroenterology, North Little Rock
Vital Prospects Clinical Research Institute, P.C., Tulsa
GI Alliance, Garland
Western States Clinical Research Inc, Wheat Ridge
Peak Gastroenterology Associates, Colorado Springs
Del Sol Research Management LLC, Tucson
FOMAT Medical Research, Glendale
Medical Associates Research Group, San Diego
United Medical Doctors, Murrieta
Ventura County Gastroenterology Medical Group Camarillo, Camarillo
Nuvance Health Medical Practice Ct, Inc., Danbury
Medical Research Center of Connecticut, Hamden
Boston Specialists, Boston
Lead Sponsor
Ellodi Pharmaceuticals, LP
INDUSTRY